immunogénicité – English Translation – Keybot Dictionary

Spacer TTN Translation Network TTN TTN Login Deutsch Français Spacer Help
Source Languages Target Languages
Dictionary
&nbsp;<a href='https://iate.europa.eu/home'>IATE</a> 2841
immunogénicité => immunological reactivity

Keybot      155 Results   30 Domains
  2 Hits www.alosbi.org.tr  
Show textShow cached sourceOpen source URL
La plupart des produits biologiques sont des protéines bio-thérapeutiques, qui offrent une faible immunogénicité et des fonctions complexes très spécifiques tout en n’intervenant que de façon minimale dans les processus biologiques normaux.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine pharmapackeurope.com as primary domain
Most biologics are bio-therapeutical proteins, which offer low immunogenicity and highly specific, complex functions while interfering only minimally with normal biologic processes. This gives them the potential to replace gene therapy.
  2 Hits www.worldgastroenterology.org  
Show textShow cached sourceOpen source URL
Ces agents ont démontré leur efficacité pour améliorer la réponse à un traitement d’infliximab et peuvent être utiles afin de réduire l’immunogénicité en utilisation concomitante avec d’autres anti-TNF.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine worldgastroenterology.org as primary domain
Immunosuppressive drugs, such as 6-MP and AZA, can also be very helpful in the treatment of fistulas in CD. These agents have been shown to enhance the response to infliximab and may be useful when used concomitantly with other anti-TNF agents by reducing their immunogenicity.
  www.2025ev.de  
Show textShow cached sourceOpen source URL
Cette acquisition permet en particulier à Platine Pharma Services d’accéder à la plateforme propriétaire Immunoline™ qui sert à l’évaluation prédictive d’immunogénicité et lui donne accès à une expertise reconnue en développement d’immuno‐essais.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine innate-pharma.com as primary domain
This transaction will be a contribution in kind by Indicia in exchange for new shares in the capital of PPS. Indicia will thus hold 32% of Platine Pharma Services. Innate Pharma and Transgene support this transaction which will allow Platine Pharma Services to accelerate its development through access to new businesses and new clients.
  www.meningvax.org  
Show textShow cached sourceOpen source URL
Considérant en particulier les résultats préliminaires sur l’immunogénicité du nouveau vaccin conjugué anti-méningocoque A et la possibilité de son introduction à brève échéance dans les pays à risque,
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine meningvax.org as primary domain
Considering, in particular, the preliminary results of the immunogenicity of the new meningococcal A conjugate vaccine and the possibility of introducing it before long in countries at risk;
  www.ladydavis.ca  
Show textShow cached sourceOpen source URL
Son laboratoire s'intéresse aussi aux mécanismes fondamentaux sous-jacents à l'immunogénicité du vaccin à ADN et il comprend un programme dynamique axé sur l'élucidation des réactions immunitaires innées à l'ADN étranger.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine ladydavis.ca as primary domain
Dr. Zaharatos’ research focuses on two major themes. Using DNA vaccines as a flexible platform for vaccine innovation and experimentation, the Zaharatos lab works on rational vector, immunogen, and adjuvant design, including ways of guiding immunogens toward antigen-presentation pathways that enhance B-cell and CD4 T-helper responses. The ultimate goal of this work is to create potent DNA vaccines targeting viral envelope glycoproteins such as HIV-1 gp120 and influenza virus hemagglutinin. The laboratory is also interested in the basic mechanisms underlying DNA vaccine immunogenicity and has an active program centered on deciphering innate immune responses to foreign DNA.
  camr-rcam.hc-sc.gc.ca  
Show textShow cached sourceOpen source URL
évalueront l'innocuité et l'immunogénicité d'un nouveau vaccin contre la pandémie de grippe;
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine camr-rcam.hc-sc.gc.ca as primary domain
assess the safety and immunogenicity of a novel pandemic influenza vaccine
  www.listeriosis-listeriose.investigation-enquete.gc.ca  
Show textShow cached sourceOpen source URL
De plus, la glycosylation des plantes est une barrière importante à l’administration parentérale de produits biopharmaceutiques à base de plantes en raison des préoccupations relatives à l’immunogénicité potentielle.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine listeriosis-listeriose.investigation-enquete.gc.ca as primary domain
Until recently, low accumulation levels have been the major bottleneck for plant-made recombinant protein production. However, several breakthroughs have been described in the past few years allowing for very high accumulation levels, mainly through chloroplast transformation and transient expression, coupled with subcellular targeting and protein fusions. Another important factor influencing our ability to use plants for the production of recombinant proteins is the availability of quick and simple purification strategies. Recent developpments using oleosin, zein, ELP and hydrophobin fusion tags have shown promise as efficient and cost-effective methods for nonchromatographic separation. Furthermore, plant glycosylation is a major barrier to the parenteral administration of plantmade biopharmaceuticals because of potential immunogenicity concerns. A major effort has been invested in humanizing plant glycosylation, and several groups have been able to reduce or eliminate immunogenic glycans while introducing mammalian-specific glycans. Finally, biosafety issues and public perception are essential for the acceptance of plants as bioreactors for the production of proteins. Over recent years, it has become clear that food and feed plants carry an inherent risk of contaminating our food supply, and thus much effort has focused on the use of non-food plants. Presently, Nicotiana benthamiana has emerged as the preferred host for transient expression, while tobacco is most frequently used for chloroplast transformation. In this review, we focus on the main issues hindering the economical production of recombinant proteins in plants, describing the current efforts for addressing these limitations, and we include an extensive list of recent patents generated with the intention of solving these limitations.
  9 Hits bella-manufactory.lu  
Show textShow cached sourceOpen source URL
Tests d'immunogénicité
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine sgs.ca as primary domain
Immunogenecity testing
  www5.agr.gc.ca  
Show textShow cached sourceOpen source URL
De plus, la glycosylation des plantes est une barrière importante à l’administration parentérale de produits biopharmaceutiques à base de plantes en raison des préoccupations relatives à l’immunogénicité potentielle.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine www5.agr.gc.ca as primary domain
Until recently, low accumulation levels have been the major bottleneck for plant-made recombinant protein production. However, several breakthroughs have been described in the past few years allowing for very high accumulation levels, mainly through chloroplast transformation and transient expression, coupled with subcellular targeting and protein fusions. Another important factor influencing our ability to use plants for the production of recombinant proteins is the availability of quick and simple purification strategies. Recent developpments using oleosin, zein, ELP and hydrophobin fusion tags have shown promise as efficient and cost-effective methods for nonchromatographic separation. Furthermore, plant glycosylation is a major barrier to the parenteral administration of plantmade biopharmaceuticals because of potential immunogenicity concerns. A major effort has been invested in humanizing plant glycosylation, and several groups have been able to reduce or eliminate immunogenic glycans while introducing mammalian-specific glycans. Finally, biosafety issues and public perception are essential for the acceptance of plants as bioreactors for the production of proteins. Over recent years, it has become clear that food and feed plants carry an inherent risk of contaminating our food supply, and thus much effort has focused on the use of non-food plants. Presently, Nicotiana benthamiana has emerged as the preferred host for transient expression, while tobacco is most frequently used for chloroplast transformation. In this review, we focus on the main issues hindering the economical production of recombinant proteins in plants, describing the current efforts for addressing these limitations, and we include an extensive list of recent patents generated with the intention of solving these limitations.
  3 Hits www.tax.gov  
Show textShow cached sourceOpen source URL
Immunogénicité encourageante du vaccin VLA15
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine valneva.com as primary domain
No safety concerns associated with VLA15 in any treatment group
  clf2-nsi2.hc-sc.gc.ca  
Show textShow cached sourceOpen source URL
évalueront l'innocuité et l'immunogénicité d'un nouveau vaccin contre la pandémie de grippe;
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine clf2-nsi2.hc-sc.gc.ca as primary domain
assess the safety and immunogenicity of a novel pandemic influenza vaccine
  www.entrecodigos.com  
Show textShow cached sourceOpen source URL
Tests d'immunogénicité
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine sgsgroup.fr as primary domain
Immunogenecity testing
  www.tod.org.il  
Show textShow cached sourceOpen source URL
des services d’immunomonitoring (avec la plate-forme de sa filiale Platine) pour évaluer l’immunogénicité, l’activité et l’efficacité des produits lors des phases d’études précliniques et cliniques.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine institut-merieux.com as primary domain
Immunomonitoring services (through its subsidiary Platine) to evaluate  the immunogenicity, activity, and efficacy of products during pre-clinical and clinical trial phases.
  45 Hits hc-sc.gc.ca  
Show textShow cached sourceOpen source URL
Questions - Immunogénicité
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine hc-sc.gc.ca as primary domain
Questions - Immunogenicity
  9 Hits www.hivnet.ubc.ca  
Show textShow cached sourceOpen source URL
Étude d’innocuité et d’immunogénicité de phase I sur le CpG ODN 7909 comme immunomodulateur et adjuvant au vaccin Engerix®-B chez des patients VIH-positifs traités par HAART.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine hivnet.ubc.ca as primary domain
Phase I Safety and Immunogenicity Study of CpG ODN 7909 as an Immune Modulator and Adjuvant to Engerix®-B Vaccine in Haart-Treated, HIV-Positive Patients.
  45 Hits www.hc-sc.gc.ca  
Show textShow cached sourceOpen source URL
Questions - Immunogénicité
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine hc-sc.gc.ca as primary domain
Questions - Immunogenicity
  www.wma.net  
Show textShow cached sourceOpen source URL
Délibérément ou par inadvertance, la modification génétique de certains microorganismes pourrait engendrer de nouveaux organismes plus virulents, résistants aux antibiotiques ou plus stables dans l'environnement. La manipulation de ces microorganismes peut modifier leur immunogénicité, leur permettant ainsi de briser les barrières immunitaires naturelles ou induites par la vaccinothérapie.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine wma.net as primary domain
All who participate in biomedical research have a moral and ethical obligation to consider the implications of possible malicious use of their findings. Through deliberate or inadvertent means, genetic modification of microorganisms could create organisms that are more virulent, are antibiotic-resistant, or have greater stability in the environment. Genetic modification of microorganisms could alter their immunogenicity, allowing them to evade natural- and vaccine-induced immunity. Advances in genetic engineering and gene therapy may allow modification of the immune response system of the target population to increase or decrease susceptibility to a pathogen or disrupt the functioning of normal host genes.
  6 Hits www.chuv.ch  
Show textShow cached sourceOpen source URL
Essai clinique de phase I en double aveugle, randomisé et contrôlé par placebo pour évaluer l'innocuité et l'immunogénicité du BCG et d'AERAS-404 administrés en primo-immunisation à des adultes VIH-négatifs, TB-négatifs et BCG-naïfs.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine chuv.ch as primary domain
Yellow fever immunization with vaccine strain YF-17D is a classic example of a safe and efficient live attenuated vaccine. A single dose induces a durable protection due to neutralizing antibodies and YF-specific T cell responses.
  www.agr.ca  
Show textShow cached sourceOpen source URL
De plus, la glycosylation des plantes est une barrière importante à l’administration parentérale de produits biopharmaceutiques à base de plantes en raison des préoccupations relatives à l’immunogénicité potentielle.
Compare text pagesCompare HTM pagesOpen source URLOpen target URLDefine agr.ca as primary domain
Until recently, low accumulation levels have been the major bottleneck for plant-made recombinant protein production. However, several breakthroughs have been described in the past few years allowing for very high accumulation levels, mainly through chloroplast transformation and transient expression, coupled with subcellular targeting and protein fusions. Another important factor influencing our ability to use plants for the production of recombinant proteins is the availability of quick and simple purification strategies. Recent developpments using oleosin, zein, ELP and hydrophobin fusion tags have shown promise as efficient and cost-effective methods for nonchromatographic separation. Furthermore, plant glycosylation is a major barrier to the parenteral administration of plantmade biopharmaceuticals because of potential immunogenicity concerns. A major effort has been invested in humanizing plant glycosylation, and several groups have been able to reduce or eliminate immunogenic glycans while introducing mammalian-specific glycans. Finally, biosafety issues and public perception are essential for the acceptance of plants as bioreactors for the production of proteins. Over recent years, it has become clear that food and feed plants carry an inherent risk of contaminating our food supply, and thus much effort has focused on the use of non-food plants. Presently, Nicotiana benthamiana has emerged as the preferred host for transient expression, while tobacco is most frequently used for chloroplast transformation. In this review, we focus on the main issues hindering the economical production of recombinant proteins in plants, describing the current efforts for addressing these limitations, and we include an extensive list of recent patents generated with the intention of solving these limitations.